Moderna (MRNA.O) received European regulatory approval for its dual flu-COVID vaccine on Tuesday, becoming the inaugural mRNA immunization to safeguard against both respiratory illnesses in adults 50 years and above.
This regulatory achievement offers Moderna a promising new income source as the biotechnology...